Physician profile
Christopher Kang
NPI 1447226808
$12,647.73
in general payments reported to CMS, 2019-2025
55 companies · $1,400 in 2025
The $1,400 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,320 · 2020: $1,860 · 2021: $2,320 · 2022: $2,377 · 2023: $1,716 · 2024: $1,654 · 2025: $1,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,770.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,079.49 | 2019-2025 | |
| Amarin Pharma, INC. | $1,933.68 | 2019-2023 | |
| Gilead Sciences, INC. | $909.62 | 2019-2025 | |
| Amgen INC. | $876.22 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $838.48 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $714.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sumitomo Pharma America, INC. | $524.72 | 2023-2025 | Gemtesa |
| Abbott Laboratories | $333.51 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Kowa Pharmaceuticals America, INC. | $309.93 | 2019-2025 | Seglentis, Livalo, Zoryve |
| Nestle Healthcare Nutrition INC. | $302.24 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $239.52 | 2019-2023 | |
| Eisai INC. | $219.15 | 2020-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $213.35 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $210.83 | 2020-2025 | Airsupra, Farxiga |
| Arbor Pharmaceuticals, INC. | $207.15 | 2019-2022 |
Show all 55 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $204.12 | 2019-2025 | Veozah |
| Merz North America, INC. | $200.00 | 2022 | |
| Pfizer INC. | $198.92 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.70 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $147.65 | 2022-2024 | |
| Aimmune Therapeutics, INC. | $143.45 | 2024-2025 | Zenpep |
| Vivus LLC | $140.55 | 2021-2025 | Pancreaze, Qsymia |
| Exact Sciences Corporation | $119.16 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $113.36 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $101.62 | 2023-2025 | Edarbi, Horizant, Edarbyclor |
| Novartis Pharmaceuticals Corporation | $96.92 | 2019-2021 | |
| Dexcom, INC. | $91.63 | 2023-2025 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $71.25 | 2024-2025 | Voquezna |
| Redhill Biopharma INC. | $69.03 | 2021-2022 | |
| Corium, LLC | $61.76 | 2023 | Adlarity |
| Allergan, INC. | $59.23 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $52.49 | 2022 | |
| Scilex Pharmaceuticals INC. | $50.89 | 2023-2025 | Ztlido |
| Genentech USA, INC. | $50.43 | 2019-2021 | |
| Radius Health, INC. | $46.95 | 2020-2024 | Tymlos |
| Medtronic, INC. | $46.94 | 2025 | Intellis Adaptivestim |
| Dynavax Technologies Corporation | $41.72 | 2021-2022 | |
| Octapharma USA, INC. | $39.40 | 2025 | Fibryga |
| Alexion Pharmaceuticals, INC. | $37.54 | 2020-2025 | Ultomiris |
| Esperion Therapeutics, INC. | $36.43 | 2024 | Nexletol |
| Ardelyx, INC. | $35.09 | 2023-2024 | Ibsrela |
| Galderma Laboratories, L.P. | $32.12 | 2022 | |
| Corcept Therapeutics | $31.26 | 2025 | Korlym |
| Sanofi Pasteur INC. | $27.68 | 2019-2023 | |
| Horizon Therapeutics Plc | $26.52 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $23.09 | 2021 | |
| Averitas Pharma INC. | $21.56 | 2024 | Qutenza |
| Ucb, INC. | $18.66 | 2025 | Bimzelx |
| Teva Pharmaceuticals USA, INC. | $18.57 | 2021 | |
| Vital Connect, INC | $17.84 | 2025 | Vitalpatch Rtm |
| Shield Therapeutics INC | $15.31 | 2025 | |
| Xeris Pharmaceuticals, INC. | $14.56 | 2022 | |
| Linus Health, INC. | $14.37 | 2023 | |
| Ibsa Pharma INC. | $14.33 | 2022 | |
| Glaxosmithkline, LLC. | $14.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.